Financial Shenanigans

Financial Shenanigans

Centene's reported numbers are best described as honestly ugly, not deceptively dressed up. The FY2025 (13.53) loss per share was driven by a $6.7B non-cash goodwill writedown that management took voluntarily under a quantitative test triggered by share-price decline and the OBBBA legislation. That said, three signals warrant active monitoring: a 27% receivables build that crashed FY2024 operating cash flow to $154M against $3.3B of net income, a premium-deficiency-reserve whipsaw that establishes, expands, and releases $389M inside a single year, and a master receivable-purchase agreement signed February 13, 2026 that allows up to $4.0B of CMS Part D receivables to be sold and recorded as an operating-cash-flow inflow. We assign a forensic risk score of 48 / Elevated — the cleaner-than-feared base, plus material judgment-driven estimates and a fresh receivables-factoring facility, define the watch list. The single data point that would most change the grade is whether the February 2026 facility is actually drawn in FY2026 — utilization would push us toward High, non-utilization would push us toward Watch.

The Forensic Verdict

Shenanigans scorecard — all 13 categories

Three reds (big-bath impairment, the new factoring facility, the working-capital whipsaw) sit alongside six yellows that are largely explained by sector mechanics. Notably clean: revenue recognition, capitalization policy, related-party exposure, and capex-as-investing presentation. The reds are about scale of judgment estimates and disclosure choices, not about distortion of revenue or earnings recognition.

Breeding Ground

The governance and incentive backdrop has loosened the natural restraint against big-bath accounting and "one-time" gain recycling, but stops well short of the structural conditions that signal manipulation risk.

The breeding ground is mid-cycle yellow: a relatively new CEO, an activist-renewed board, an adjusted-EPS-driven comp plan, and a 2025 admission that the compliance program needed enterprise-wide redesign. There is no founder dominance, no auditor red flag, no restatement, and no material weakness. Compensation tied to adjusted EPS is the most direct manipulation incentive — but in FY2025 the metric collapsed anyway, so the system did not visibly reward earnings management.

Earnings Quality

Reported earnings carry meaningful judgment risk, concentrated in three places: the medical-claims liability, the risk-adjustment estimate, and the goodwill carrying value. Each is disclosed; each can swing the printed number by billions.

Cash flow vs net income — multi-year

The five-year aggregate CFO of $24.2B against five-year aggregate net income of $5.9B (CFO/NI of ~4.1x) looks artificially strong because three years (FY20, FY22, FY23) absorbed acquired working capital from WellCare and Magellan and benefited from positive risk-adjustment receivable timing. The single-year CFO ratio swings from 6.7x (FY2023) to 0.05x (FY2024), which means the cash-flow signal is unreadable without normalization. FY2024 is the clearest red flag: net income up year-on-year, CFO down 98%, FCF turned negative.

Receivables vs revenue growth

The two years where receivables grew materially faster than revenue are FY2021 (+12.8pp gap, the WellCare integration year) and FY2024 (+21.0pp gap, the year of the new third-party PBM transition and Medicaid retro receivables). FY2025 reversed: receivables fell 8.2% as PBM rebate timing normalized, supporting the "timing" rather than "fictitious receivables" interpretation. The forensic test is clean on average over a cycle, but the FY2024 single-year divergence is the largest in the series.

One-time and divestiture income flows

A 17-line list of "non-recurring" items spanning four years is itself the signal. Centene runs a continuous portfolio cleanup: 12 announced divestitures since 2023, with adjustments to prior gains booked years after the original transaction (Magellan Rx received purchase-price adjustments in 2023 and 2025). None of these items individually rises to "shenanigan" — but every one of them lands in management's "other adjustments" line on the adjusted-EPS reconciliation, smoothing the headline non-GAAP metric.

Premium deficiency reserve whipsaw

The PDR balance went from $92M at FY2024 close to $389M mid-FY2025 to zero at FY2025 close. Management's reason — "based on the progression of earnings during the year (with higher earnings at the beginning of the year and lower at the end of the year, given cost sharing progression)" — is technically defensible. But establish-then-release behavior inside a single year is the textbook signature of a flexible reserve, and the reversal flowed straight back to adjusted EPS in Q3-Q4 FY2025. Worth tracking in FY2026 against the no-PDR-recorded posture.

Cash Flow Quality

Operating cash flow is directionally real but mechanically lumpy — and a new factoring facility introduces a forward-looking distortion risk that did not exist in prior reports.

Working-capital contribution to operating cash flow

The yellow bars (working capital plus other reconciling items) drive the entire CFO/NI gap. In FY2024 the net working-capital effect is roughly (3.2)B, the largest in a decade. In FY2025 the net effect (after adding back the $6.7B goodwill impairment and $513M Magellan write) is roughly +11.8B. Both years are in the same direction as management's explanation: the FY2024 receivables build genuinely became cash in FY2025. A reader using the trailing two-year average of $2.6B CFO/yr is closer to truth than either single year.

The new CMS Part D receivable purchase agreement

This facility did not exist before February 2026. The $4.0B receivable balance ($4,000M) represents 79% of FY2025 reported CFO of $5,088M. Drawing the full amount in FY2026 would mechanically add $3.8-4.0B to operating cash flow (net of the discount), and Centene's CFO would look like a continuation of FY2025's recovery when in fact it would be partly a one-time sale of a regulator receivable. This is the single highest-priority forensic disclosure to monitor in the FY2026 filings.

Free cash flow after acquisitions

Centene has been a net divester since 2022, not an acquirer, so acquisition-adjusted FCF largely tracks reported FCF. The cleaner read is that the company has not used M&A to manufacture cash flow during the analysis window — the WellCare and Magellan-era acquired working capital benefits are concentrated in FY2020-FY2022 and have largely flushed through.

Metric Hygiene

The biggest hygiene issue is the size of the FY2025 "other adjustments" line on the adjusted-EPS bridge — it is larger in absolute value than the GAAP loss it reconciles from.

Non-GAAP reconciliation hygiene

The "other adjustments" of $14.86 per share in FY2025 is approximately $7.4B before tax — exceeding total reported impairments of $7.3B because it also includes minor exit costs, real estate losses, and a Magellan Rx tweak. Management's adjustments are itemized in footnote 1 of the bridge, and the components are reasonable individually. The forensic concern is structural: in 2025 the company effectively recasts the income statement as if a $7B portfolio reset never happened, while the cash that funded the original M&A premium is permanent. Investors need to underwrite the full GAAP loss, not the adjusted figure, when sizing equity value.

KPI definition drift

Two items in this list are first-order forensic questions. First, days in claims payable fell from 53 to 46 in FY2025 while HBR rose 360 basis points — a faster claims-payment cadence in a year of accelerating cost trend is unusual and worth a direct question to management. Second, a $14B reclassification from current to non-current liabilities between FY2024 and FY2025 is not explained in the MD&A. The most plausible explanation is a remapping of long-duration medical claims liability and Part D risk-sharing payables, but the absence of a narrative footnote is itself a yellow flag.

Severity profile across the playbook

What to Underwrite Next

The accounting risk is not a thesis breaker; it is a valuation haircut and a position-sizing limiter. The company is not hiding economic reality, but the size and quantity of judgment-driven estimates mean reported earnings can move several billion dollars year-on-year without any operating change. A long position should be sized assuming the next forensic surprise is more likely than not.

Highest-value items to track in the next two filings

Decisive view

Centene is not a fraud or revenue-recognition story. It is an unusually large managed-care company whose reported earnings and cash flow are heavily shaped by judgment estimates (medical claims liability of $20.5B, risk-adjustment receivables/payables, PDR, goodwill carrying value), whose adjusted-EPS metric in FY2025 mechanically excludes the largest single charge in the company's history, and whose newly signed receivable-factoring facility creates a forward channel for cash-flow flattering that did not exist before. We grade this 48 / Elevated: meaningful enough to demand a valuation discount and a position cap, but not severe enough to call it a thesis breaker. The single forward signal that would most change the grade is whether the February 2026 receivable purchase agreement is drawn during FY2026 — utilization without explicit, prominent disclosure in the cash-flow statement narrative would tip this to High and reduce the credibility of management's clean-CFO claim.